Skye Bioscience Inc.(US:SKYE) Globenewswire·2025-12-12 21:16Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company [3] - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3] Group 3: Case Allegations - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the company's business and prospects [4] - Specific claims include that nimacimab was less effective than represented, leading to overstated clinical and commercial prospects [4] - The lawsuit asserts that when the true information became public, investors suffered damages [4]